Insmed Incorporated (LON:0JAV)

Market Cap	11.61B
Revenue (ttm)	290.52M
Net Income (ttm)	-729.89M
Shares Out	n/a
EPS (ttm)	-4.45
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	676
Average Volume	1,700
Open	84.48
Previous Close	83.83
Day's Range	81.00 - 84.82
52-Week Range	16.59 - 83.84
Beta	1.12
RSI	59.40
Earnings Date	Feb 20, 2025

About Insmed

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil P...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 912
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JAV

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD